Affordable Weight Loss Drugs Set to Transform Global Healthcare Access
For years, the exorbitant cost of weight loss medications has placed them beyond the reach of the average patient, creating a significant barrier to treatment. However, a seismic shift is imminent. Within days, millions of individuals across the globe are poised to gain access to Ozempic and Wegovy for as little as $15 per month, or approximately $3 per dose. This dramatic price reduction stems from the impending expiration of patents in several key countries, which will allow other pharmaceutical companies to manufacture generic versions of these drugs.
Patent Expirations Unlock New Markets
In the United States, patents for these medications remain firmly in place until 2032, meaning American patients must endure another six years before accessing discounted generics. Currently, without insurance coverage, costs in the US range from $340 to over $1,300 monthly. In stark contrast, India will see the patent for semaglutide—the active ingredient in both Ozempic and Wegovy—expire on March 20. This milestone will enable numerous companies to produce affordable generic alternatives for the first time.
This year, patents are also scheduled to expire in China, Canada, Brazil, Turkey, and South Africa, collectively home to around 40 percent of the world's population. Siddharth Mittal, CEO of an Indian manufacturer planning to sell generic semaglutide, remarked, 'I don't think there has ever been so much excitement for any class of drug going off patent.'
Regulatory and Market Dynamics
It will not be possible to sell generic versions in the US due to the ongoing patent protection, despite their availability elsewhere. During recent shortages of brand-name versions, some pharmacies had produced cheaper generics, but regulators are now clamping down, citing adequate US supply. Meanwhile, Eli Lilly's Mounjaro and Zepbound, which contain tirzepatide, are protected by patents in the US until 2036.
In India alone, more than 40 companies are expected to launch over 50 generic brands within the next week. While these generics are not Ozempic or Wegovy themselves, they contain the same active drug, semaglutide, and are anticipated to drive significant price reductions in markets where patents have lapsed.
Celebrity Influence and Public Interest
Weight loss drugs have surged in popularity, often dubbed Hollywood's worst-kept secret for their ability to facilitate weight loss with just a weekly injection. Celebrities such as Rebel Wilson, Amy Schumer, and Oprah Winfrey have publicly acknowledged using these medications, fueling widespread interest. Estimates suggest about one in seven Americans has tried the drugs, with another one in seven expressing interest. In the US, approximately 42 percent of adults are obese, and 30 percent are overweight, highlighting the substantial demand.
Health Considerations and Global Impact
Doctors prescribe these drugs for type 2 diabetes and weight loss but emphasize the importance of combining them with a high-protein diet and exercise to mitigate risks like muscle wastage and frailty. Wegovy is approved for both conditions, while Ozempic is officially for diabetes but can be prescribed off-label for weight loss.
In India, where over 180 million adults are overweight or obese, more than $100 million was spent on weight loss drugs in 2025. Generic manufacturers have not yet disclosed pricing plans, but analysts predict costs could drop to $15 monthly. Salil Kallianpur, an independent analyst, warned, 'With high demand, falling prices and multiple brands, you may see direct pharmacy purchases, distributor-level leakages, or cosmetic or lifestyle use, especially in urban markets. This could lead to misuse, poor titration and unmanaged side effects and eventually regulatory tightening.'
Vishal, a 32-year-old tech worker in Hyderabad using Wegovy, is among those considering a switch, stating, 'I will consult my doctor to check if I can move to a generic version, as that appears to be lighter on the pocket.'
Patent Extensions and International Variations
Generally, patents last about 20 years from filing but can be extended due to delays. In the US, Novo Nordisk, semaglutide's manufacturer, received a patent extension because of lengthy development and regulatory approval processes, with Ozempic not approved until December 2017. Such protections do not exist in countries like India. In Canada, no extension was granted, and Novo Nordisk ceased paying its annual $290 maintenance fee, leading to patent expiration in 2026. In China, ten companies are already preparing to sell generic versions, with at least a dozen more having completed clinical trials.
As these changes unfold, weight loss drugs continue to be among the most profitable and fastest-growing products in the pharmaceutical industry, poised to reshape healthcare accessibility on a global scale.
